Alnylam Pharma (ALNY) Posts Smaller-than-Expected Q1 Loss
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $236.91 +3.63%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
ZTO, AMMX, AFIB, More
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
ZTO, AMMX, AFIB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.22), $0.25 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $30.15 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- Target raises full-year sales forecast amid ongoing turnaround drive
- Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
